BRPI0215050B8 - compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem - Google Patents

compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem

Info

Publication number
BRPI0215050B8
BRPI0215050B8 BRPI0215050A BR0215050A BRPI0215050B8 BR PI0215050 B8 BRPI0215050 B8 BR PI0215050B8 BR PI0215050 A BRPI0215050 A BR PI0215050A BR 0215050 A BR0215050 A BR 0215050A BR PI0215050 B8 BRPI0215050 B8 BR PI0215050B8
Authority
BR
Brazil
Prior art keywords
heterocyclic
receptor binding
chemokine
allergic
inflammatory
Prior art date
Application number
BRPI0215050A
Other languages
English (en)
Other versions
BR0215050A (pt
BR0215050B1 (pt
Inventor
Kaller Al
Atsma Bem
Dennis Smith Christopher
Harwig Curtis
Bogucki David
Schols Dominique
J Mceachern Ernest
J Bridger Gary
Crawford Jason
Rosaria Di Fluri Maria
T Skerlj Renato
Nan Siqiao
Wilson Trevor
Zhou Yuanxi
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of BR0215050A publication Critical patent/BR0215050A/pt
Publication of BR0215050B1 publication Critical patent/BR0215050B1/pt
Publication of BRPI0215050B8 publication Critical patent/BRPI0215050B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)

Abstract

"compostos heterocíclicos de ligação a receptor de quimiocina com eficácia realçada". esta invenção refere-se a compostos heterocíclicos consistindo de um átomo de nitrogênio de núcleo circundado por três grupos pendentes, onde dois dos três grupos pendentes são preferivelmente metil de benzimidazolila e tetraidroquinolila, e o terceiro grupo pendente contém n e opcionalmente contém anéis adicionais. os compostos ligam-se a receptores de quimiocina, incluindo cxcr4 e ccr5, e demonstram efeitos protetores contra infecção de células alvo por um vírus de imunodeficiência humana (hiv).
BRPI0215050A 2001-12-21 2002-12-23 compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem BRPI0215050B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34271601P 2001-12-21 2001-12-21
US35082202P 2002-01-17 2002-01-17
PCT/US2002/041407 WO2003055876A1 (en) 2001-12-21 2002-12-23 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Publications (3)

Publication Number Publication Date
BR0215050A BR0215050A (pt) 2004-10-13
BR0215050B1 BR0215050B1 (pt) 2017-11-14
BRPI0215050B8 true BRPI0215050B8 (pt) 2021-05-25

Family

ID=26993156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0215050A BRPI0215050B8 (pt) 2001-12-21 2002-12-23 compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem

Country Status (17)

Country Link
US (2) US20030220341A1 (pt)
EP (1) EP1465889B1 (pt)
JP (1) JP4556020B2 (pt)
KR (1) KR20040068339A (pt)
CN (2) CN102153540A (pt)
AU (1) AU2002357379A1 (pt)
BR (1) BRPI0215050B8 (pt)
CA (1) CA2467718C (pt)
ES (1) ES2623982T3 (pt)
HU (1) HUP0402458A2 (pt)
IL (2) IL161784A0 (pt)
MX (1) MXPA04006136A (pt)
NO (1) NO20042578L (pt)
NZ (1) NZ533542A (pt)
PL (1) PL369856A1 (pt)
RU (1) RU2325387C2 (pt)
WO (1) WO2003055876A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1411918E (pt) 2001-07-31 2012-03-06 Genzyme Global S A R L Métodos para mobilizar células progenitoras/estaminais
JP4556020B2 (ja) 2001-12-21 2010-10-06 ジェンザイム・コーポレーション 高い有効性を有するケモカインレセプタ結合複素環式化合物
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7498323B2 (en) * 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
BRPI0508703B8 (pt) * 2004-03-15 2021-05-25 Anormed Inc processo para a síntese de um antagonista de cxcr4
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
CN1329374C (zh) * 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
JP2008508357A (ja) * 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション 化学的化合物
US20080045537A1 (en) * 2004-08-16 2008-02-21 Kristjan Gudmundsson Chemical Compounds
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
JP2008511669A (ja) * 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2006038989A1 (en) * 2004-09-29 2006-04-13 Chemocentryx, Inc. Substituted arylamides
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
WO2007022523A2 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
ES2407115T3 (es) * 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
EP2407171A3 (en) 2006-02-02 2012-04-11 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
JP5257068B2 (ja) * 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
SI2195023T1 (en) * 2007-08-29 2018-07-31 Sanofi Humanized anti-CXCR5 antibodies, their derivatives and their uses
CN102015717A (zh) * 2008-03-28 2011-04-13 奥蒂瑞斯治疗公司 趋化因子受体调节剂
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
EP2447263A1 (en) 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
AU2011310592B2 (en) * 2010-09-29 2015-01-22 Intervet International B.V. N-heteroaryl compounds
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
CN103694142A (zh) * 2013-11-28 2014-04-02 浙江科技学院 4-N-Boc-氨基环己酮的制备方法
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
US11433048B2 (en) 2016-06-16 2022-09-06 Centre National De La Recherche Scientifique CXCR4 receptor-binding compounds useful for increasing interferon level
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN106478367B (zh) * 2016-09-30 2019-01-11 兰州大学 一种合成氯胺酮的中间体化合物以及氯胺酮的合成方法
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
AU2018225556A1 (en) * 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111655261A (zh) * 2017-12-19 2020-09-11 X4 制药有限公司 非环状cxcr4抑制剂和其用途
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
WO2019183133A1 (en) 2018-03-19 2019-09-26 Emory University Pan-Tropic Entry Inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CN111777529A (zh) * 2019-04-03 2020-10-16 复旦大学 一种1，4/1，5-氨基醇化合物及其制备方法
CA3177537A1 (en) 2020-05-01 2021-11-04 Isaiah Arkin E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
CN112142673B (zh) * 2020-09-18 2023-06-30 聊城大学 芳基烯烃唑类衍生物及其制备方法和用途
CN112898178A (zh) * 2021-01-25 2021-06-04 蚌埠产品质量监督检验研究院 一种N-Boc-反式-1,4-环己二胺的制备方法
WO2022220725A1 (en) 2021-04-16 2022-10-20 Edouard Zamaratski Lpxh inhibitors as anti-infective agents
US11931360B2 (en) * 2021-06-23 2024-03-19 Wayne State University Compositions and methods relating to inhibitors of pro-inflammatory factors for treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US69234A (en) * 1867-09-24 James w
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
US20341A (en) * 1858-05-25 Carpet-fastener
US4933447A (en) * 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
JP2003524620A (ja) * 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PL360932A1 (en) * 2000-09-15 2004-09-20 Anormed Inc. Chemokine receptor binding heterocyclic compounds
JP2004508421A (ja) 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
BR0113932A (pt) * 2000-09-15 2003-06-24 Anormed Inc Compostos heterocìclicos que se ligam ao receptor da quimiocina
EP1343505A1 (en) * 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
PT1411918E (pt) 2001-07-31 2012-03-06 Genzyme Global S A R L Métodos para mobilizar células progenitoras/estaminais
JP4556020B2 (ja) 2001-12-21 2010-10-06 ジェンザイム・コーポレーション 高い有効性を有するケモカインレセプタ結合複素環式化合物

Also Published As

Publication number Publication date
NO20042578L (no) 2004-09-07
BR0215050A (pt) 2004-10-13
JP2005518397A (ja) 2005-06-23
CN102153540A (zh) 2011-08-17
IL161784A0 (en) 2005-11-20
CA2467718C (en) 2011-04-26
US20030220341A1 (en) 2003-11-27
MXPA04006136A (es) 2004-11-01
KR20040068339A (ko) 2004-07-30
RU2325387C2 (ru) 2008-05-27
US20060100240A1 (en) 2006-05-11
WO2003055876A1 (en) 2003-07-10
EP1465889B1 (en) 2017-03-22
JP4556020B2 (ja) 2010-10-06
EP1465889A4 (en) 2008-05-14
EP1465889A1 (en) 2004-10-13
ES2623982T3 (es) 2017-07-12
NZ533542A (en) 2007-04-27
HUP0402458A2 (hu) 2005-07-28
IL161784A (en) 2011-07-31
CN1596255A (zh) 2005-03-16
AU2002357379A1 (en) 2003-07-15
US7354934B2 (en) 2008-04-08
BR0215050B1 (pt) 2017-11-14
PL369856A1 (en) 2005-05-02
CA2467718A1 (en) 2003-07-10
RU2004122406A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
BRPI0215050B8 (pt) compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem
WO2004106493A3 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
BRPI0414862A (pt) derivados de tropano substituìdos com imidazopiridina com atividade antagonista do receptor ccr5, para o tratamento do hiv e da inflamação
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
EA200401167A1 (ru) Производные тропана в качестве модуляторов ccr5
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0113286B1 (pt) pirazàis substituÍdos e composiÇço farmacÊutica compreendendo os mesmos.
TW200701981A (en) Heterocyclic antiviral compounds
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
WO2007022371A3 (en) Chemokine receptor binding compounds
BRPI0512410A (pt) compostos de amido e seu uso como produtos farmacêuticos
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
NZ610315A (en) Antiviral condensed heterocyclic compounds
EA200700725A1 (ru) ПРИМЕНЕНИЕ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИН
ATE427318T1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
BR0208572A (pt) Derivados de aminopiperidina
TR199802769T2 (xx) Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/12/2022